ABSTRACT
Recent clinical trials have refined our understanding of how the glycoprotein (GP) IIb/IIIa inhibitors should best be used. These trials examined whether there are clinical differences between agents, whether empiric use of GP IIb/IIIa inhibitors in acute coronary syndromes is justified, and whether these drugs might allow for early invasive management in acute coronary syndromes.
Footnotes
↵* The author has indicated that he has received grant or research support from the Centocor, Eli Lilly, and Merck corporations.
- Copyright © 2001 The Cleveland Clinic Foundation. All Rights Reserved.